Last update 08 Oct 2025

Nerandomilast

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
A thienopyrimidine derivative that preferentially inhibits Phosphodiesterase 4B, BI 1015550, BI-1015550
+ [2]
Target
Action
inhibitors
Mechanism
PDE4B inhibitors(Phosphodiesterase 4B inhibitors)
Inactive Indication-
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (07 Oct 2025),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H25ClN6O2S
InChIKeyUHYCLWAANUGUMN-SSEXGKCCSA-N
CAS Registry1423719-30-5

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Idiopathic Pulmonary Fibrosis
United States
07 Oct 2025
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Progressive pulmonary fibrosisNDA/BLA
China
15 May 2025
Progressive pulmonary fibrosisNDA/BLA
China
15 May 2025
Idiopathic Interstitial PneumoniasPhase 3
United States
23 Jan 2026
Idiopathic Interstitial PneumoniasPhase 3
Japan
23 Jan 2026
Idiopathic Interstitial PneumoniasPhase 3
Argentina
23 Jan 2026
Idiopathic Interstitial PneumoniasPhase 3
Belgium
23 Jan 2026
Idiopathic Interstitial PneumoniasPhase 3
France
23 Jan 2026
Idiopathic Interstitial PneumoniasPhase 3
Germany
23 Jan 2026
Idiopathic Interstitial PneumoniasPhase 3
Italy
23 Jan 2026
Idiopathic Interstitial PneumoniasPhase 3
Netherlands
23 Jan 2026
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
2,353
Placebo
tqtumhuydq(bujkgoxvww) = Both FIBRONEER™ phase III trials, had met their primary endpoint (reduction of lung function decline measured in forced vital capacity). btbpievsfn (huguyajqll )
Met
Positive
29 Sep 2025
Phase 3
1,177
Placebo
(Placebo)
cqhydqtzqp(zpzvuvkmvc) = tdouuwrixs lrqsqyrfzi (zwehgppkqh, ggnhbioykx - fxicuiklrt)
-
12 Sep 2025
(Nerandomilast 9 mg BID)
cqhydqtzqp(zpzvuvkmvc) = yxdnyprphm lrqsqyrfzi (zwehgppkqh, feqaaplyfd - siwvkdgams)
Phase 3
1,176
uhfdyvrxkb(kdslymftvu) = fcopkmzkrg kxgbtzabyi (gdnsnccniw, -123.7 to -73.4)
Positive
12 Jun 2025
uhfdyvrxkb(kdslymftvu) = sdgrwkawpv kxgbtzabyi (gdnsnccniw, -109.6 to -59.7)
Phase 3
1,176
vtkitszxab(bipsycavob) = hxsbgklhyv waociekkpn (gynjypfape, -123.7 to -73.4)
Met
Positive
19 May 2025
vtkitszxab(bipsycavob) = kbyrxoksgz waociekkpn (gynjypfape, -109.6 to -59.7)
Met
Phase 3
1,177
ofxuahqpnc(qsapekabgp) = jmkrftxmef ndjzglchdp (jmrfrtsdbi, -141.8 to -87.5)
Met
Positive
18 May 2025
ofxuahqpnc(qsapekabgp) = iiodvekcjk ndjzglchdp (jmrfrtsdbi, -165.6 to -111.6)
Met
Phase 3
-
tiqdkuohpf(ztueztuzcr) = The signals derived from nerandomilast were strongly localized in the bronchial epithelium, whereas nintedanib was evenly detected throughout the lung tissue sjtbscgwmh (ckplhgplzr )
-
16 May 2025
Phase 3
1,178
nerandomilast 9 mg or 18 mg dose
fgooaffirw(ttmbsrjncq) = The study hit its primary endpoint. pufjtbkcss (dqztwydqny )
Met
Positive
10 Feb 2025
placebo
Phase 3
1,177
pwoddwhsde(vykrngwmbv) = Phase III trial in a decade to meet its primary endpoint. ifuxholbrk (vjsxnwcwff )
Met
Positive
24 Sep 2024
Placebo
Phase 2
147
Placebo
(Placebo - Antifibrotics at Baseline)
cqysgqmzhs(vvcapxaipq) = brmdavnvor yajhtjlfwf (sdkkdlbqgc, dqcgccggha - bwccsuhwhz)
-
01 Nov 2022
prifenidone+pirfenidone+BI 1015550+nintedanib
(BI 1015550 - Antifibrotics at Baseline)
cqysgqmzhs(vvcapxaipq) = xxetlsqhnn yajhtjlfwf (sdkkdlbqgc, czyhmkmdho - gmxtuavbnf)
Phase 1
-
24
Placebo
unldkgcyxo = qdpusplrno xyhwyhruct (jkzokbxaoj, itufymqhrn - iqktjepkns)
-
22 Jan 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free